科前生物：获批猪圆环病毒2型重组杆状病毒灭活疫苗新兽药证书

Core Viewpoint - The company has received approval for its recombinant inactivated vaccine for Porcine Circovirus Type 2, which will enhance its product offerings and competitiveness in the market [1] Group 1: Product Approval - The vaccine has been approved by the Ministry of Agriculture and Rural Affairs and has received the New Veterinary Drug Registration Certificate [1] - The registration classification of the vaccine is categorized as Class III, with a monitoring period of three years [1] Group 2: Vaccine Efficacy - The vaccine is intended to prevent infections caused by Porcine Circovirus Type 2, providing active immunity that lasts for four months after 28 days of administration [1] - Passive immunity for piglets lasts until 21 days of age [1] Group 3: Market Impact - The approval of the product will diversify the company's product range and enhance its competitive position in the industry [1] - However, the timeline for production and sales remains uncertain pending the acquisition of the necessary approval number [1]